← Back to Search

Other

LY3502970 for Obesity

Phase 2

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 36

Summary

This trial is testing a new drug called LY3502970 to see if it can help people who are overweight or have obesity lose weight.

Eligible Conditions

Obesity

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 36

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 36

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 36 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Change From Baseline in BMI in LY3502970 and Placebo

Change From Baseline in Body Weight in LY3502970 and Placebo

Change From Baseline in Waist Circumference in LY3502970 and Placebo

+3 more

Side effects data

From 2022 Phase 2 trial • 383 Patients • NCT05048719

38%

Nausea

21%

Vomiting

16%

Diarrhoea

13%

Constipation

Fatigue

Covid-19

Lipase increased

Dyspepsia

Gastrooesophageal reflux disease

Palpitations

Abdominal distension

Decreased appetite

Eructation

Weight decreased

Arthralgia

Headache

Urticaria

Abdominal pain upper

Upper respiratory tract infection

Muscle spasms

Dizziness

Hypertension

100%

80%

60%

40%

20%

Study treatment Arm

12 mg LY3502970

24 mg LY3502970

36 mg LY3502970 - 1

36 mg LY3502970 - 2

45 mg LY3502970 - 1

Placebo

3 mg LY3502970

45 mg LY3502970 - 2

1.5 mg Dulaglutide

Trial Design

7Treatment groups

Experimental Treatment

Placebo Group

Group I: 45 mg-2 LY3502970Experimental Treatment1 Intervention

Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

Group II: 45 mg-1 LY3502970Experimental Treatment1 Intervention

Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

Group III: 36 mg-2 LY3502970Experimental Treatment1 Intervention

Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

Group IV: 36 mg-1 LY3502970Experimental Treatment1 Intervention

Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

Group V: 24 mg LY3502970Experimental Treatment1 Intervention

Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.

Group VI: 12 milligram (mg) LY3502970Experimental Treatment1 Intervention

Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.

Group VII: PlaceboPlacebo Group1 Intervention

Participants received placebo administered orally once daily until 36 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

LY3502970

2021

Completed Phase 2

~1270

Do I qualify?Apply below to find out